Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
57 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Options
  • Trading Ideas

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights
Today, 7:11 AM
  On Friday, 1043 companies hit new 52-week lows.

AAOI

Read More
4 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

55 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin
Today, 7:11 AM
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.

AOSL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Strong Buy on CareDx, Lowers Price Target to $45

By Benzinga Newsdesk
Today, 7:11 AM
Raymond James analyst Andrew Cooper maintains CareDx (NASDAQ:CDNA) with a Strong Buy and lowers the price target from $52 to $45.

CDNA

Read More
30 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For May 5, 2022

By Benzinga Insights
Today, 7:11 AM
  Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

AAOI

Read More
2 minute read
  • News

CareDx Reports Over 200,000 Heart Transplant Patient Results Served

By Benzinga Newsdesk
Today, 7:11 AM
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and

CDNA

Read More
2 minute read
  • Biotech
  • General

CareDx Partners With The European Society For Organ Transplantation To ‘Provide Clinical Evidence Supporting the Use of AlloSeq cfDNA with European Transplant Healthcare Professionals’

By Bill Haddad
Today, 7:11 AM
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and

CDNA

Read More
1 minute read
  • Legal
  • News

CareDx Wins $44.9M In Damages In Trial Against Natera; $21.2M In Compensatory Damages And $23.7M In Punitive Damages.

By Bill Haddad
Today, 7:11 AM
-Reuters

CDNA

Read More
32 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Options
  • Trading Ideas

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights
Today, 7:11 AM
    On Monday, 524 stocks hit new 52-week lows.

AAL

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Raymond James Maintains Strong Buy on CareDx, Lowers Price Target to $52

By Benzinga Newsdesk
Today, 7:11 AM
Raymond James analyst Andrew Cooper maintains CareDx (NASDAQ:CDNA) with a Strong Buy and lowers the price target from $90 to $52.

CDNA

Read More
4 minute read
  • Biotech
  • Earnings
  • FDA
  • General
  • News
  • Penny Stocks
  • Small Cap
  • Top Stories

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline
Today, 7:11 AM
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

Posts navigation

Previous 1 … 3 4 5 … 9 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service